Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
A phase 2 trial of Relacorilant and Gemcitabine in pancreatic ductal adenocarcinoma, run by Corcept Therapeutics, now recruiting.
Overview
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma is a phase 2 interventional study registered as NCT07259317 by Corcept Therapeutics, with 80 participants planned, started 2026-01-27 and due to reach its primary completion in 2027-09. Interventions recorded: Relacorilant, Nab-paclitaxel and Gemcitabine.
Similar pages
not linked directly; found by shared links- TrialRelacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Shares Relacorilant, Corcept Therapeutics and the tag pipeline.
- TrialTwo Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Shares Corcept Therapeutics and the tag pipeline.
- TrialStudy of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialEvaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialClinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialPolymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.